SUTRO BIOPHARMA INC (STRO)
Health Care · NASDAQ
Sutro Biopharma is a clinical-stage oncology company developing site-specific and novel-format antibody drug conjugates (ADCs), bispecific ADCs, immunostimulatory ADCs, and dual-payload ADCs enabled by its proprietary…
What SUTRO BIOPHARMA INC does
Sutro Biopharma is a clinical-stage oncology company developing site-specific and novel-format antibody drug conjugates (ADCs), bispecific ADCs, immunostimulatory ADCs, and dual-payload ADCs enabled by its proprietary XpressCF® and XpressCF+® cell-free protein synthesis platforms. The company's lead program is STRO-004, a single homogeneous ADC targeting tissue factor currently in Phase 1 trials for solid tumors, with preclinical assets STRO-006 (targeting integrin alpha v beta 6) and STRO-227 (a dual-payload ADC targeting PTK7). Sutro collaborates with leading pharma companies including Astellas, Merck, Celgene/BMS, and EMD Serono on multiple oncology programs.
Themes: ["antibody drug conjugates (ADCs)","oncology / cancer therapeutics","cell-free protein synthesis","site-specific conjugation","bispecific therapeutics","immunostimulatory ADCs","novel protein engineering"]
Fundamentals
- Price$29.99 as of 2026-07-09 close
- Market cap$500M as of 2026-07-10
- 1-year return+281.6% as of 2026-07-09 close
- Net margin-154.2% as of 2026-07-10
- ROE-223.8% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+49.9% as of 2026-07-10
- Revenue CAGR (3y)+14.8% SEC XBRL
- Beta1.49 as of 2026-07-10
Key risks (from latest filing)
["Company has a history of significant losses and may never achieve profitability; currently unprofitable with -154% net margin as of July 2026.","Substantial additional funding required to advance development of product candidates; risk of inability to secure adequate capital on reasonable terms to continue development and operations.","Lead product STRO-004 and other candidates are in early clinical/preclinical stages and may fail, face competitive pressures, or experience significant development delays that could materially harm commercial viability; Nasdaq listing compliance risk due to stock price not meeting minimum listing requirements."]
Competitors & peers
- Seagen Inc. (SGEN)
- Genmab A/S
- Immunocore
- Gritstone bio
- Alnylam Pharmaceuticals (ALNY)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.